Schwartz Jamie McElrath, Ng Derek K, Roem Jennifer, Padmanabhan Nikhil, Romero Daniel, Joe Jessica, Campbell Christopher, Sigal George B, Wohlstadter Jacob N, Everett Allen D, Bembea Melania M
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Resusc Plus. 2024 Mar 22;18:100609. doi: 10.1016/j.resplu.2024.100609. eCollection 2024 Jun.
We sought to determine if higher plasma levels of brain injury biomarkers neurofilament light (NfL), phosphorylated tau 181 (pT181), tau, and ubiquitin C-terminal hydrolase L1 (UCHL1) were associated with unfavorable outcomes in children supported on extracorporeal membrane oxygenation (ECMO) with and without preceding cardiac arrest.
We conducted a secondary analysis of a two-center prospective observational study of ECMO patients 0-<18 years. Plasma concentrations of NfL, pT181, tau, and UCHL1 were measured on ECMO days 1, 2 and 3. Unfavorable outcome was defined as in-hospital mortality or discharge Pediatric Cerebral Performance Category (PCPC) >2 with decline from baseline PCPC among survivors.
Among 88 children on ECMO, mean tau levels were significantly higher on each of the first three ECMO days in children who underwent extracorporeal cardiopulmonary resuscitation (ECPR) compared to those with non-ECPR cardiac arrest or with no cardiac arrest preceding ECMO. Higher ECMO day 1 tau levels were significantly associated with increased hazard of unfavorable outcome in unadjusted (HR, 1.35, 95% CI 1.09-1.66) and adjusted (HR, 1.42; 95% CI 1.13-1.79) models. Higher levels of NfL or pT181 were not associated with increased hazard for unfavorable outcome in multivariable models. UCHL1 values were outside of detectable limits and thus deferred from analysis.
Levels of tau were significantly associated with increased hazard of death or unfavorable neurologic outcome in unadjusted and adjusted models. Biomarkers of brain injury, particularly tau, may aid in detection of neurologic injury and neuroprognostication in patients on ECMO with and without preceding cardiac arrest.
我们试图确定,在接受体外膜肺氧合(ECMO)支持的儿童中,无论之前是否发生心脏骤停,较高的血浆脑损伤生物标志物神经丝轻链(NfL)、磷酸化tau181(pT181)、tau和泛素C末端水解酶L1(UCHL1)水平是否与不良预后相关。
我们对一项针对0至<18岁ECMO患者的两中心前瞻性观察性研究进行了二次分析。在ECMO第1、2和3天测量NfL、pT181、tau和UCHL1的血浆浓度。不良预后定义为住院死亡率或出院时小儿脑功能分类(PCPC)>2且幸存者的PCPC较基线下降。
在88例接受ECMO治疗的儿童中,与未进行体外心肺复苏(ECPR)的心脏骤停或ECMO前未发生心脏骤停的儿童相比,接受ECPR的儿童在ECMO的前三天中,平均tau水平均显著更高。在未调整(风险比[HR],1.35,95%置信区间[CI] 1.09 - 1.66)和调整(HR,1.42;95% CI 1.13 - 1.79)模型中,较高的ECMO第1天tau水平与不良预后风险增加显著相关。在多变量模型中,较高的NfL或pT181水平与不良预后风险增加无关。UCHL1值超出可检测范围,因此未纳入分析。
在未调整和调整模型中,tau水平与死亡风险增加或不良神经预后显著相关。脑损伤生物标志物,尤其是tau,可能有助于检测接受ECMO治疗的患者(无论之前是否发生心脏骤停)的神经损伤和进行神经预后评估。